CRISPR Therapeutics AG (LTS:0VRQ) Float Percentage Of Total Shares Outstanding: 87.58% (As of Jul. 04, 2026)


LTS:0VRQ CRISPR Therapeutics AG LTS:0VRQ
46 GF Score
Price $59.25
GF Value $2.74
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is CRISPR Therapeutics AG Float Percentage Of Total Shares Outstanding?

CRISPR Therapeutics AG LTS:0VRQ 46 Float Percentage Of Total Shares Outstanding is 87.58% as of Jul. 04, 2026. GuruFocus rates LTS:0VRQ with a GF Score™ of 46/100 and a GF Value™ of $2.74 (Significantly Overvalued). The stock has 3 warning signs investors should review.

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, CRISPR Therapeutics AG's float shares is 86.25 Mil. CRISPR Therapeutics AG's total shares outstanding is 98.48 Mil. CRISPR Therapeutics AG's float percentage of total shares outstanding is 87.58%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, CRISPR Therapeutics AG's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, CRISPR Therapeutics AG's Institutional Ownership is 61.19%.

LTS:0VRQ
46GF Score
CRISPR Therapeutics AG LTS:0VRQ
Float Percentage Of Total Shares Outstanding is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CRISPR Therapeutics AG Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

CRISPR Therapeutics AG's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=86.25/98.48
=87.58%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Float Percentage Of Total Shares Outstanding of 87.58% mean?
CRISPR Therapeutics AG (LTS:0VRQ) has a Float Percentage Of Total Shares Outstanding of 87.58% as of Jul. 04, 2026. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on CRISPR Therapeutics AG and its competitors.
Is CRISPR Therapeutics AG's Float Percentage Of Total Shares Outstanding too high?
CRISPR Therapeutics AG's current Float Percentage Of Total Shares Outstanding is 87.58%. Overall, CRISPR Therapeutics AG has a GF Score™ of 46/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CRISPR Therapeutics AG's Float Percentage Of Total Shares Outstanding compare to ORKA and TVTX?
CRISPR Therapeutics AG's Float Percentage Of Total Shares Outstanding of 87.58% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Float Percentage Of Total Shares Outstanding for a Biotechnology company?
A good Float Percentage Of Total Shares Outstanding depends on the Biotechnology industry context. However, Float Percentage Of Total Shares Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Float Percentage Of Total Shares Outstanding mean?
A high Float Percentage Of Total Shares Outstanding can signal that a stock is expensive relative to its fundamentals. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on CRISPR Therapeutics AG and its competitors. CRISPR Therapeutics AG's current Float Percentage Of Total Shares Outstanding is 87.58%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CRISPR Therapeutics AG stock overvalued right now?
Based on GuruFocus' analysis, CRISPR Therapeutics AG (LTS:0VRQ) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.74, compared to a current price of $59.25 — trading 2062.4% above its estimated fair value. The current Float Percentage Of Total Shares Outstanding is 87.58%. CRISPR Therapeutics AG's overall GF Score™ is 46/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Float Percentage Of Total Shares Outstanding calculated?
Float Percentage Of Total Shares Outstanding is calculated from a company's financial statements. For CRISPR Therapeutics AG (LTS:0VRQ), the current Float Percentage Of Total Shares Outstanding is 87.58% as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CRISPR Therapeutics AG (LTS:0VRQ) Overvalued in 2026?

Based on GuruFocus' analysis, CRISPR Therapeutics AG stock appears to be overvalued. The current stock price of $59.25 is trading 2062.4% above its estimated GF Value™ of $2.74. GuruFocus considers CRISPR Therapeutics AG to be Significantly Overvalued.

Key valuation signals for LTS:0VRQ:

  • Float Percentage Of Total Shares Outstanding: 87.58%
  • GF Value™: $2.74 vs. price of $59.25 (2062.4% above fair value)
  • GF Score™: 46/100 with 3 warning signs

No single metric tells the full story. See the LTS:0VRQ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CRISPR Therapeutics AG Business Description

Address Baarerstrasse 14, Zug, CHE, 6300
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
46GF Score

Get the complete analysis for LTS:0VRQ

Float Percentage Of Total Shares Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$59.25
Price
$2.74
GF Value